Prometheus™ - the curative potential of gene therapy for large unmet clinical needs.
While gene therapy has been a subject of extensive research for over 50 years, with more than 62,000 publications on PubMed and 1,000 registered trials on ClinicalTrials.gov, the approvals of the previous decade have been focused on rare diseases. Recent advances in vector design and nucleic acid technologies now allow for the use of gene therapy in a broad range of therapeutic indications, bringing its curative potential to common ailments, at an affordable cost. Remedium has developed Prometheus™ - a revolutionary platform that enables replacement of subcutaneously delivered proteins, as a safe, durable, and pharmacokinetically-optimized, single injection gene therapy – for a fraction of the current treatment costs.
Hollander JM, Goraltchouk A, Rawal M, Liu J, Luppino F, Zeng L, Seregin A. Adeno-Associated Virus-Delivered Fibroblast Growth Factor 18 Gene Therapy Promotes Cartilage Anabolism. Cartilage. 2023 Mar 6. LINK
Goraltchouk A, Hollander JM, Luppino F, Zeng L, Seregin A. Characterization of Novel FGF18 Gene Therapy for the Treatment of Osteoarthritis. Poster session presented at: Annual Meeting of the ASBMR; 2022 Sep 9-12; Austin, TX. LINK
ors podium presentation
Goraltchouk A, Hollander JM, Luppino F, Zeng L, Seregin A. AAV2-hFGF18 Increases Cartilage Thickness and Promotes Hyaline Cartilage Anabolism. Paper presented at: Orthopaedic Research Society; 2023 Feb 10-14; Dallas, TX. LINK
oarsi podium presentation
Goraltchouk A, Hollander JM, Luppino F, Zeng L, Seregin A. Novel AAV2-FGF18 Chondrogenic Gene Therapy. Osteoarthritis and Cartilage, Volume 31, Supplement 1, S52-S53, March 2023. LINK
Goraltchouk A, Hollander JM, Luppino F, Zeng L, Seregin A. Novel AAV2-FGF18 Gene Therapy Promotes Cartilage Anabolism. Paper presented at: Veterinary Orthopedic Society; 2023 Mar 11-18; Big Sky, MT. LINK
Goraltchouk A, Luppino F, Seregin A. Treatment with rhFGF18 Analog Results in Cerebroprotection and Recovery of Motor and Memory Function in a Rat Model of Acute Ischemic Stroke. Poster session presented at: American Academy of Neurology; 2023 Apr 23; Boston, MA. LINK
A vector is the method of delivery for the genetic material, it can be viral, lipid, or polymeric (with or without targeting).
GENE OF INTEREST
The cargo typically contains a gene or genetic sequence of interest, this gene can express a protein that treats the disease.
The cargo is the genetic construct delivered by the vector, it can be DNA, RNA, or other nucleic acid derivative.
Expression of the therapeutic protein can be regulated by a tissue- or cell-specific promoter and other genetic elements.
Get In Touch
We are always interested in starting a new conversation and are looking forward to hearing from you. Thank you in advance for your inquiry and please have a wonderful day!
1116 Great Plain Ave, Suite 203
P: +1 (978) 467 5217